AEROVENT

Ülke: İsrail

Dil: İngilizce

Kaynak: Ministry of Health

Aktif bileşen:

IPRATROPIUM BROMIDE

Mevcut itibaren:

BOEHRINGER INGELHEIM ISRAEL LTD.

ATC kodu:

R03BB01

Farmasötik formu:

RESPIRATOR SOLUTION

Kompozisyon:

IPRATROPIUM BROMIDE 0.25 MG/ML

Uygulama yolu:

INHALATION

Reçete türü:

Required

Tarafından üretildi:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Terapötik grubu:

IPRATROPIUM BROMIDE

Terapötik alanı:

IPRATROPIUM BROMIDE

Terapötik endikasyonlar:

For the relief of symptoms of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema . Aerovent respirator solution is of particular benefit in relieving acute bronchospasm when used concomitantly with inhaled beta agonists.

Yetkilendirme tarihi:

2012-01-31

Bilgilendirme broşürü

Aerovent
Proposed patient information
Boehringer Ingelheim
November 2020
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) -
1986
This medicine is dispensed with a doctor’s prescription only
AEROVENT
®
SOLUTION FOR INHALATION
EVERY 1 ML (20 DROPS) CONTAINS:
IPRATROPIUM BROMIDE 0.25 MG
Inactive ingredients and allergens: see section 2 under ‘Important
information about
some of this medicine’s ingredients’, and section 6 ‘Additional
information'.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet
contains concise information about this medicine. If you have any
further questions,
consult your doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to
others. It may harm
them, even if it seems to you that their medical condition is similar
to yours.
1. WHAT IS THIS MEDICINE INTENDED FOR?
Relieving symptoms of reversible bronchospasm associated with asthma,
chronic
bronchitis, and emphysema.
AEROVENT is particularly effective in relieving acute bronchial
constriction when
given together with inhaled beta agonists.
THERAPEUTIC GROUP: anticholinergic.
2.
BEFORE USING THIS MEDICINE
DO NOT USE THIS MEDICINE IF:
•
You are sensitive (allergic) to the active ingredient ipratropium
bromide, to
atropine or atropine derivatives (anticholinergic active substances
with
similar structure) or to any of the other ingredients in this medicine
(listed
in section 6).
•
You are pregnant (particularly during the first three months) or are
breastfeeding, unless your doctor has recommended this treatment after
weighing the risk and benefit.
SPECIAL WARNINGS ABOUT USING THIS MEDICINE
Consult your doctor or pharmacist before using this medicine.
TALK TO YOUR DOCTOR OR PHARMACIST BEFORE USING AEROVENT IF:
•
Care must be taken to ensure that the solution or the mist from the
nebulizer
does not get into the eyes. ATROVENT should be used with special care
in
patients with a tendency to narrow-angle glaucoma. If the medicine
accidentally ge

Ürün özellikleri

Aerovent
Proposed prescribing information
Boehringer Ingelheim
January 2022
AEROVENT
IPRATROPIUM BROMIDE 0.25 MG/ML
Respirator solution for inhalation
1.
NAME OF THE MEDICINAL PRODUCT
AEROVENT
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml (20 drops) contains:
Ipratropium bromide 0.25 mg
Excipient with known effect: 0.10 mg benzalkonium chloride/ml
(corresponds to 10 µg per actuation),
see section 4.4.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
RESPIRATOR SOLUTION
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the relief of symptoms of reversible bronchospasm associated with
asthma, chronic bronchitis
and emphysema.
Aerovent respirator solution is of particular benefit in relieving
acute bronchospasm when used
concomitantly with inhaled beta agonists.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The dosage should be adapted to the individual requirements of the
patient; patients should also be kept
under medical supervision during treatment. It is advisable not to
greatly exceed the recommended daily
dose during both acute and maintenance treatment.
If therapy does not produce a significant improvement or if the
patient's condition worsens, medical
advice must be sought in order to determine a new regimen of therapy.
In the case of acute or rapidly
worsening dyspnea, a doctor should be consulted immediately.
Note: Aerovent and disodium cromoglycate inhalation solutions should
not be simultaneously
administered in the same nebulizer as precipitation may occur.
Aerovent
Proposed prescribing information
Boehringer Ingelheim
January 2022
Aerovent Respirator Solution may be administered from an intermittent
positive pressure ventilator or
from suitable nebulizers.
The following dosages are recommended:
ADULTS
0.1 - 0.5 mg (0.4 - 2.0 ml = 8-40 drops) up to 4 times daily.
CHILDREN
_6-12 Years_
: 0.25 mg (20 drops, i.e., 1 ml) 3 to 4 times daily.
_Children < 6 years of age:_
As only limited information is available for this age group, the
following dose schedule should only be
gi